Sunday, September 21, 2014
YOLO COUNTY NEWS
99 CENTS

Sickle cell drug shows promise in UCD trial

By
From page A8 | July 06, 2014 |

A UC Davis clinical trial has found safe a drug designed to treat a common, painful complication of sickle cell disease.

There are currently no specific treatments for vaso-occlusive crises, during which clumped-together blood cells hinder blood flow. It is responsible for more than 70,000 hospitalizations annually, according to Ted Wun, associate dean for research at the UCD School of Medicine.

The 15-patient trial found no severe side-effects from the drug, dubbed GMI 1070, and that it was maintaining adequate concentrations in the blood.

Published online in the journal Public Library of Science ONE, the study was not aimed at determining the drug’s effectiveness, but Wun said it did show small improvements in blood flow and reduced the markers of cell activation.

Sickle cell disease, which lowers life expectancy by 20 to 30 years, affects an estimated 90,000 to 100,000 Americans, mostly blacks, according to the U.S. Centers for Disease Control and Prevention.

It is caused by abnormal hemoglobin that contorts red blood cells into a sickle shape, making them stiff and sticky. These clumped cells reduce blood flow, leading to severe hip, back and long-bone pain, and, often, chest and abdominal pain.

“White blood cells bind to inflamed blood vessel walls and sickle red cells stick to white cells, but interestingly the initiating event is the white cells,” Wun said in a news release. “If we could interrupt that white cell interaction, we could stop the cycle that leads to vaso-occlusions.”

The new drug is designed to do that by mimicking sugars attached to cell-adhesion proteins, called selectins, reducing the stickiness and increasing blood flow.

Sickle cell most often strikes the kidneys, lungs and spleen, but it can affect any organ. Stroke, infections, hypertension and heart failure are among its severe complications.

Patients in the trial tolerated the drug well, with headaches the most common side-effect. Preliminary results of a second trial also have been positive, and have been submitted for publication, according to researchers. A third phase is planned.

“If the phase III study confirms that GMI 1070 is effective, it would be a huge advance for the sickle cell community,” Wun said.

GlycoMimetics Inc., a Maryland-based biotechnology company based in Gaithersburg, produces the new drug under the trade name Rivipansel. The company paid for the trial.

Also this week, National Institutes of Health scientists announced the results of a study that found bone marrow transplants can reverse sickle cell disease. The transplant worked in 26 of 30 adults, and 15 of them were even able to stop taking drugs that prevent rejection one year later.

The treatment is a modified version of bone marrow transplants that have worked in children. Donors are a brother or sister whose stem cell-rich bone marrow is a good match for the patient.

The treatment involves using chemotherapy and radiation to destroy bone marrow before replacing it with healthy donor marrow cells.

Results from the adult study, involving patients aged 29 on average, were published in the Journal of the American Medical Association.

—The Associated Press contributed to this report.

Comments

comments

Cory Golden

Cory Golden

The Enterprise's higher-education and congressional reporter. http://about.me/cory_golden
.

News

Elementary school counselors: necessary, but poorly funded

By Anne Ternus-Bellamy | From Page: A1 | Gallery

 
 
Bet Haverim hosts High Holy Day services

By Special to The Enterprise | From Page: A1

 
Teams assess damage as wildfire burns

By The Associated Press | From Page: A2 | Gallery

 
Driver arrested for DUI after Saturday morning crash

By Enterprise staff | From Page: A2

Help raise funds for juvenile diabetes cure

By Enterprise staff | From Page: A3

 
Jewelry, art for sale at Senior Center

By Enterprise staff | From Page: A3

Davis Community Meals needs cooks

By Enterprise staff | From Page: A3

 
Hawk Hill trip planned Sept. 30

By Enterprise staff | From Page: A4

 
UC campus chancellors granted hefty pay raises

By The Associated Press | From Page: A4

Send kids to camp!

By Enterprise staff | From Page: A4

 
Da Vinci awarded $38,000 for restorative justice program

By Anne Ternus-Bellamy | From Page: A4

Outdoor yoga marathon celebrates community

By Special to The Enterprise | From Page: A5

 
Wise words

By Sue Cockrell | From Page: A12

 
.

Forum

Awareness is key to this fight

By Creators Syndicate | From Page: B5

 
Where is this going?

By Creators Syndicate | From Page: A6

We’re living in the Golden State of emergency

By Debra DeAngelo | From Page: A6

 
Options for protection come with flu season

By The Associated Press | From Page: A6

Are we there yet? Not enough hours in the day to goof off

By Tanya Perez | From Page: A6Comments are off for this post

 
Don’t sell city greenbelt

By Letters to the Editor | From Page: A10

Paso Fino project is flawed

By Letters to the Editor | From Page: A10

 
Paso Fino — it’s not worth it

By Letters to the Editor | From Page: A10

Archer will get my vote

By Letters to the Editor | From Page: A10

 
It’s time for Davis Scouts to stand up for what is right

By Special to The Enterprise | From Page: A10

Mike Keefe cartoon

By Debbie Davis | From Page: A10

 
Building something at schools’ HQ

By Our View | From Page: A10

Speak out

By Enterprise staff | From Page: A11

 
Maybe David can beat Goliath again

By Lynne Nittler | From Page: A11 | Gallery

.

Sports

DHS gets on its Morse to beat Edison

By Thomas Oide | From Page: B1 | Gallery

 
JV Blue Devils drop low-scoring affair

By Spencer Ault | From Page: B2

 
Republic FC’s fairy tale season continues

By Evan Ream | From Page: B3 | Gallery

Wire briefs: Giants rally falls short in San Diego

By The Associated Press | From Page: B3

 
Four local swimmers qualify for Olympic Trials

By Enterprise staff | From Page: B3

‘We’re a way better team’ than record, says UCD’s Shaffer

By Bruce Gallaudet | From Page: B4 | Gallery

 
UCD roundup: Aggie men pound Pomona-Pitzer in the pool

By Enterprise staff | From Page: B4

Davis 15-year-old making a splash in European F4 series

By Bruce Gallaudet | From Page: B8 | Gallery

 
.

Features

.

Arts

‘Ladies Foursome’ adds shows

By Enterprise staff | From Page: A3

 
.

Business

UCD grad’s startup earns kudos at TechCrunch event

By Special to The Enterprise | From Page: A7

 
Styles on target for November debut

By Wendy Weitzel | From Page: A7

MBI hires VP of marketing

By Enterprise staff | From Page: A7

 
Taylor Morrison unveils new Woodland community next weekend

By Special to The Enterprise | From Page: A9 | Gallery

Rob White: What is an ‘innovation center’?

By Rob White | From Page: A9

 
.

Obituaries

Carol L. Walsh

By Special to The Enterprise | From Page: A4

 
.

Comics

Comics: Sunday, September 21, 2014

By Creator | From Page: B8